Viran Holden is an Oncology physician. OpenAlex indexes 8 publications with 1,205 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
802 E Highway 60
Monett, MO 657089311
Telephone
417-882-4880Provider last certified this registry record 9 Jul 2025.
Industry payments
55 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202521 payments
- Incyte CorporationProgram year20256 payments
- AstraZeneca Pharmaceuticals LPProgram year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
50.7%PD-1 inhibitor49.6%Pembrolizumab100%Part B, office-administered≥11 patientsKinase inhibitor0.3%Calquence22%Ibrance12%Mekinist11%Tafinlar11%Lenvima10%Everolimus9%Imbruvica9%Brukinsa9%Tagrisso8%Part D<11 patients+ 6 more classes in this area
Metabolism & gastrointestinal
22.7%Substance P/Neurokinin-1 Receptor Antagonist18.2%Aprepitant100%Part B, office-administered≥13 patientsSerotonin-3 Receptor Antagonist4.1%Palonosetron hcl88%Ondansetron hydrochloride10%Ondansetron Hcl1%Ondansetron Odt1%Part D + Part B<11 patients+ 4 more classes in this area
Musculoskeletal
19.1%RANK Ligand Inhibitor19.1%Denosumab100%Part B, office-administered≥20 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Impact of large language models on trial-to-patient matching efficiency.
Journal of Clinical Oncology
2025 - 281 JAVELIN Medley VEGF: phase 2 study of avelumab + axitinib in patients with previously treated non-small cell lung cancer (NSCLC) or treatment naive, cisplatin-ineligible urothelial cancer (UC)
Regular and Young Investigator Award Abstracts
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”